Association between serum uric acid and the Adult Treatment Panel III-defined metabolic syndrome

. Results from a single hospital database

Young Hee Rho, Jin Hyun Woo, Sungjae Choi, Young Ho Lee, Jong Dae Ji, Gwan Gyu Song

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Hyperuricemia is known to be associated with various metabolic abnormalities of the metabolic syndrome, but its precise contribution is not well defined. We have investigated the effects of serum uric acid on the metabolic syndrome as defined by the Adult Treatment Panel (ATP) III criteria and tested its independent association. This was a cross-sectional study consisting of 1686 Korean subjects (821 men and 865 women) from a health promotion center. Clinical data and the presence of the metabolic syndrome were assessed, and serum uric acid was tested for its independent contribution to the metabolic syndrome using 2 multiple logistic regression models. The metabolic syndrome was defined by the original ATP III criteria and the modified ATP III criteria that include a reduced waist circumference. The general age-adjusted prevalence of the metabolic syndrome was 4.4% in men and 6.8% in women; hyperuricemic subjects tended to have a higher prevalence of the metabolic syndrome and more metabolic abnormalities than normouricemic subjects. The prevalence of the metabolic syndrome increased as normouricemia (2.9%) progressed to hyperuricemia (8.9%) and to gout (43.6%) in men. Multivariate analysis showed that serum uric acid was a significant factor for the development of the metabolic syndrome as defined by the original ATP III criteria only in one model for women (odds ratio, 1.51; 95% confidence interval, 1.11-2.05; P = .009). Serum uric acid is closely linked to and may even be independently associated with the metabolic syndrome as defined by the ATP III criteria, but only in women.

Original languageEnglish
Pages (from-to)71-76
Number of pages6
JournalMetabolism: Clinical and Experimental
Volume57
Issue number1
DOIs
Publication statusPublished - 2008 Jan 1

Fingerprint

Uric Acid
Databases
Serum
Therapeutics
Hyperuricemia
Logistic Models
Gout
Waist Circumference
Women's Health
Health Promotion
Multivariate Analysis
Cross-Sectional Studies
Odds Ratio
Confidence Intervals

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

@article{119112205b6b4960ac45c7dd78a3439c,
title = "Association between serum uric acid and the Adult Treatment Panel III-defined metabolic syndrome: . Results from a single hospital database",
abstract = "Hyperuricemia is known to be associated with various metabolic abnormalities of the metabolic syndrome, but its precise contribution is not well defined. We have investigated the effects of serum uric acid on the metabolic syndrome as defined by the Adult Treatment Panel (ATP) III criteria and tested its independent association. This was a cross-sectional study consisting of 1686 Korean subjects (821 men and 865 women) from a health promotion center. Clinical data and the presence of the metabolic syndrome were assessed, and serum uric acid was tested for its independent contribution to the metabolic syndrome using 2 multiple logistic regression models. The metabolic syndrome was defined by the original ATP III criteria and the modified ATP III criteria that include a reduced waist circumference. The general age-adjusted prevalence of the metabolic syndrome was 4.4{\%} in men and 6.8{\%} in women; hyperuricemic subjects tended to have a higher prevalence of the metabolic syndrome and more metabolic abnormalities than normouricemic subjects. The prevalence of the metabolic syndrome increased as normouricemia (2.9{\%}) progressed to hyperuricemia (8.9{\%}) and to gout (43.6{\%}) in men. Multivariate analysis showed that serum uric acid was a significant factor for the development of the metabolic syndrome as defined by the original ATP III criteria only in one model for women (odds ratio, 1.51; 95{\%} confidence interval, 1.11-2.05; P = .009). Serum uric acid is closely linked to and may even be independently associated with the metabolic syndrome as defined by the ATP III criteria, but only in women.",
author = "Rho, {Young Hee} and Woo, {Jin Hyun} and Sungjae Choi and Lee, {Young Ho} and Ji, {Jong Dae} and Song, {Gwan Gyu}",
year = "2008",
month = "1",
day = "1",
doi = "10.1016/j.metabol.2007.08.008",
language = "English",
volume = "57",
pages = "71--76",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Association between serum uric acid and the Adult Treatment Panel III-defined metabolic syndrome

T2 - . Results from a single hospital database

AU - Rho, Young Hee

AU - Woo, Jin Hyun

AU - Choi, Sungjae

AU - Lee, Young Ho

AU - Ji, Jong Dae

AU - Song, Gwan Gyu

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Hyperuricemia is known to be associated with various metabolic abnormalities of the metabolic syndrome, but its precise contribution is not well defined. We have investigated the effects of serum uric acid on the metabolic syndrome as defined by the Adult Treatment Panel (ATP) III criteria and tested its independent association. This was a cross-sectional study consisting of 1686 Korean subjects (821 men and 865 women) from a health promotion center. Clinical data and the presence of the metabolic syndrome were assessed, and serum uric acid was tested for its independent contribution to the metabolic syndrome using 2 multiple logistic regression models. The metabolic syndrome was defined by the original ATP III criteria and the modified ATP III criteria that include a reduced waist circumference. The general age-adjusted prevalence of the metabolic syndrome was 4.4% in men and 6.8% in women; hyperuricemic subjects tended to have a higher prevalence of the metabolic syndrome and more metabolic abnormalities than normouricemic subjects. The prevalence of the metabolic syndrome increased as normouricemia (2.9%) progressed to hyperuricemia (8.9%) and to gout (43.6%) in men. Multivariate analysis showed that serum uric acid was a significant factor for the development of the metabolic syndrome as defined by the original ATP III criteria only in one model for women (odds ratio, 1.51; 95% confidence interval, 1.11-2.05; P = .009). Serum uric acid is closely linked to and may even be independently associated with the metabolic syndrome as defined by the ATP III criteria, but only in women.

AB - Hyperuricemia is known to be associated with various metabolic abnormalities of the metabolic syndrome, but its precise contribution is not well defined. We have investigated the effects of serum uric acid on the metabolic syndrome as defined by the Adult Treatment Panel (ATP) III criteria and tested its independent association. This was a cross-sectional study consisting of 1686 Korean subjects (821 men and 865 women) from a health promotion center. Clinical data and the presence of the metabolic syndrome were assessed, and serum uric acid was tested for its independent contribution to the metabolic syndrome using 2 multiple logistic regression models. The metabolic syndrome was defined by the original ATP III criteria and the modified ATP III criteria that include a reduced waist circumference. The general age-adjusted prevalence of the metabolic syndrome was 4.4% in men and 6.8% in women; hyperuricemic subjects tended to have a higher prevalence of the metabolic syndrome and more metabolic abnormalities than normouricemic subjects. The prevalence of the metabolic syndrome increased as normouricemia (2.9%) progressed to hyperuricemia (8.9%) and to gout (43.6%) in men. Multivariate analysis showed that serum uric acid was a significant factor for the development of the metabolic syndrome as defined by the original ATP III criteria only in one model for women (odds ratio, 1.51; 95% confidence interval, 1.11-2.05; P = .009). Serum uric acid is closely linked to and may even be independently associated with the metabolic syndrome as defined by the ATP III criteria, but only in women.

UR - http://www.scopus.com/inward/record.url?scp=36849041596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36849041596&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2007.08.008

DO - 10.1016/j.metabol.2007.08.008

M3 - Article

VL - 57

SP - 71

EP - 76

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 1

ER -